Phase 2 N=42 Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
ALK Gene Mutation · BRAF Gene Mutation · EGFR Gene Mutation
Primary: Overall Response Rate (ORR) — 6; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=359 Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Schizophrenia
Primary: Change From Baseline to Week 4 in the PANSS Total Score — -14.28; -13.95; -16.08; -9.27 score on a scale — p=0.0009
Phase 2 N=275 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Chronic Hepatitis C Virus · Hepatitis C, Chronic · Hepatitis C
Primary: Percentage of Subjects Achieving Sustained Virologic Response at 12 Weeks Post-treatment (SVR12) — 210 Participants
Phase 2 N=47 SNIFF - Combo INI+EMPA Trial
Mild Cognitive Impairment · Cognitive Impairment · Alzheimer Disease
Primary: Number of Participants With Treatment-Related Serious Adverse Events as Assessed by CTCAE v5.0 — 0; 0; 0; 0 participants
Phase 2 N=276 Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Advanced Solid Tumor
Primary: Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above — 2; 5; 6; 2 Participants
Phase 2 N=40 Open-Label of SPN-820 in Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Each Time Point in the Hamilton Depression Rating Scale-6 Items (HAM-D6) Total Score (HAM-D6). — -6.1; -7.2; -7.5; -7.8 score on a scale
Phase 2 N=25 A Study of Colesevelam for Lenalidomide-Associated Diarrhea
Multiple Myeloma · Diarrhea
Primary: Number of Participants With Improvement of Lenalidomide-associated Diarrhea Evaluated by CTCAE 5.0 — 22; 3 Participants
Phase 2 N=65 Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: FDG-PET/CT Standardized Uptake Value at 12 Months — 69; 27; 69; 30 Standardized Uptake Value (SUV)
Phase 2 N=50 Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Stage IIIC Fallopian Tube Cancer · Stage IIIC Ovarian Cancer · Stage IIIC Primary Peritoneal Cancer
Primary: Quality of Life (QOL) Assessed Using Functional Assessment of Cancer Therapy-Ovarian Questionnaire (FACT-O) — 116.32 score on a scale
Phase 2 N=36 BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Efficacy of Vemurafenib — 10; 14; 12 Participants
Phase 2 N=37 Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Primary: Recommended Phase II Dose — 5 mg/m^2
Phase 2 N=27 Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Recurrent Pericarditis
Primary: 11-point NRS Pain Score — -3.7 units on a scale
Phase 2 N=25 A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Spinal Muscular Atrophy
Primary: Time to Death or Respiratory Intervention — NA months
Phase 2 N=388 PRV-015 in Gluten-free Diet Non-responsive Celiac Disease
Celiac Disease
Primary: Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24 — -1.32; -1.28; -1.21; -1.28 score on a scale…
Phase 2 N=157 A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Cardiac Edema (CHF)
Primary: Change in Body Weight From Baseline to Last Assessment Time Point (the Day After IMP Administration) by Day 8 — -1.96; -1.74; -1.4; -1.84 kg